Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Otton

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology and Therapeutics|January 1, 1982
Sparteine metabolism in Canadian CaucasiansA Vinks, T Inaba, S V Otton, et al.
Clinical Pharmacology and Therapeutics|March 1, 1983
Comparative pharmacogenetics of sparteine and debrisoquineT Inaba, A Vinks, S V Otton, et al.
British Journal of Addiction|December 1, 1991
Drug metabolism and interactions in abuse liability assessmentE M Sellers, S V Otton, U E Busto
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 1, 1988
In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liverS V Otton, R U Brinn, L F Gram
Canadian Journal of Physiology and Pharmacology|January 1, 1982
In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquineS V Otton, T Inaba, W A Mahon, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1995
Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the ratD Wu, S V Otton, W Kalow, et al.
Canadian Journal of Physiology and Pharmacology|September 1, 1980
Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and OrientalsW Kalow, S V Otton, D Kadar, et al.
British Journal of Clinical Pharmacology|August 1, 1986
Sparteine oxidation is practically abolished in quinidine-treated patientsR Brinn, K Brøsen, L F Gram, et al.
Canadian Journal of Physiology and Pharmacology|July 1, 1984
A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenaseT Inaba, M Nakano, S V Otton, et al.
Biochemical Pharmacology|June 1, 1997
Interactions of amphetamine analogs with human liver CYP2D6D Wu, S V Otton, T Inaba, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|January 1, 1982
Sparteine metabolism in Canadian CaucasiansA Vinks, T Inaba, S V Otton, et al.
Clinical Pharmacology and Therapeutics|March 1, 1983
Comparative pharmacogenetics of sparteine and debrisoquineT Inaba, A Vinks, S V Otton, et al.
British Journal of Addiction|December 1, 1991
Drug metabolism and interactions in abuse liability assessmentE M Sellers, S V Otton, U E Busto
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 1, 1988
In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liverS V Otton, R U Brinn, L F Gram
Canadian Journal of Physiology and Pharmacology|January 1, 1982
In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquineS V Otton, T Inaba, W A Mahon, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1995
Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the ratD Wu, S V Otton, W Kalow, et al.
Canadian Journal of Physiology and Pharmacology|September 1, 1980
Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and OrientalsW Kalow, S V Otton, D Kadar, et al.
British Journal of Clinical Pharmacology|August 1, 1986
Sparteine oxidation is practically abolished in quinidine-treated patientsR Brinn, K Brøsen, L F Gram, et al.
Canadian Journal of Physiology and Pharmacology|July 1, 1984
A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenaseT Inaba, M Nakano, S V Otton, et al.
Biochemical Pharmacology|June 1, 1997
Interactions of amphetamine analogs with human liver CYP2D6D Wu, S V Otton, T Inaba, et al.
Pageof 4